

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 July 2020 (30.07.2020)



(10) International Publication Number
WO 2020/152193 A1

(51) International Patent Classification:

A61K 31/4709 (2006.01) **G01N 33/48** (2006.01)
A61K 31/567 (2006.01) **A61P 17/02** (2006.01)
A61K 31/573 (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2020/051457

(22) International Filing Date:

22 January 2020 (22.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19153026.0 22 January 2019 (22.01.2019) EP
19170117.6 18 April 2019 (18.04.2019) EP

(71) Applicant: **AKRIBES BIOMEDICAL GMBH** [AT/AT];
Campus Vienna Biocenter 5, 1030 Wien (AT).

(72) Inventors: **WOLFF-WINISKI, Barbara**; Maurer Lange
Gasse 137/9, 1230 Wien (AT). **STÜTZ, Anton**; Teichweg
4, 4813 Altmünster (AT). **SCHÖFMANN, Nicole**; Kaiser
Ebersdorferstrasse 35/2, 1110 Wien (AT). **DÖRFLER, Pe-
tra**; Dr. Julius Wengraf-Strasse 22, 2345 Brunn am Gebirge
(AT).

(74) Agent: **PINTSCH, Tanja**; Patentanwälte Isenbruck
Bösl Hörschler PartG mbB, Prinzregentenstr. 68, 81675
München (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING

(57) Abstract: The present invention relates to a Selective Glucocorticoid Receptor Modulator (SEGRM), or a pharmaceutically acceptable salt thereof, for use in the treatment of impaired skin wound healing in a subject, an in vitro method for identifying a subject suffering from impaired skin wound healing to be responsive to the treatment with a Selective Glucocorticoid Receptor Modulator (SEGRM), or a pharmaceutically acceptable salt thereof, and kits and kits-of-part related thereto.



WO 2020/152193 A1